オミクロン対策に!【鼻うがい】でコロナ陽性者の重症化・死亡率が1/8に!

感染再拡大中の今だから知ってほしい鼻うがいの重要性

ニールメッド株式会社が米国オーガスタ大学の研究に鼻うがい「サイナスリンス」を提供。COVID-19陽性者を対象に1日2回2週間、鼻うがいを実施させた結果、重症化・死亡率が 1/8 になったという研究結果が発表されました。(CDC=アメリカ疾病管理センター COVID-19 症例監視データと比較)

感染再拡大中の今だから知ってほしい鼻うがいの重要性

鼻から吸い込まれる空気にはウィルスや細菌、花粉などの異物がたくさん。その約7割が上咽頭から体内に取り込まれると言われています。PCR検査で細胞をこすり取られる鼻の奥の部分が上咽頭です。上咽頭にウィルスが付着している状態が陽性であり、PCR検査で陽性になったとしても感染しているとは限りません。陽性確認後に「鼻うがい」をすることで重症化・死亡率が1/8になること、つまりコロナ感染症の感染リスクも抑えられるということが米国オーガスタ大学の研究で明らかになりました。

Importance SARS-CoV-2 enters the nasopharynx to replicate; mechanical debridement with nasal irrigation soon after diagnosis could reduce morbidity and mortality. Objective To determine whether initiating nasal irrigation after COVID-19 diagnosis reduces hospitalizations and death, and whether irrigant composition impacts severity. Design Unblinded randomized clinical trial of two nasal irrigation protocols in outpatients PCR positive for SARS-CoV-2, nested in a prospective case:cohort using laboratory-confirmed cases in the CDC COVID-19 Case Surveillance dataset. Setting Single-lab community testing facility associated with the emergency department (ED) in Augusta, GA. Participants A consecutive sample of outpatients 55 years and older were contacted from daily COVID-19+ lab reports between September 24 and December 21 of 2020. Patients without supplemental oxygen use or cognitive barriers agreeing to same-day irrigation initiation were remotely consented. Among 826 screened, 321 were unable to be reached, 132 were ineligible, 294 refused participation, and 79 participants were enrolled. Interventions Participants were randomly assigned adding 2.5 mL povidone-iodine 10% or 2.5 mL sodium bicarbonate to 240ml of isotonic nasal irrigation twice daily for 14 days. Main Outcomes and Measures The primary outcome was hospitalization or death from COVID-19 within 28 days of enrollment by daily self-report confirmed with phone calls and hospital records, compared to the CDC Surveillance Dataset covering the same time. Secondary outcomes compared symptom resolution by irrigant additive. Results Seventy-nine participants were enrolled (mean [SD] age, 64 [8] years; 36 [46%] women; 71% Non-Hispanic White). Analyzed by intention-to-treat, by day 28, COVID-19 symptoms resulted in 1/42 hospitalizations in those irrigating with alkalinization, 0/37 in the povidone-iodine group, (1.27%) and no deaths. Of nearly three million CDC cases, 9.14% were known to be hospitalized, with an additional 1.5% mortality in those without hospitalization data. The total risk of hospitalization or death (10.6%) was 8.4 times that of enrolled patients (SE=2.74; P=.006). 62 completed daily surveys (78%), averaging 1.8 irrigations/day. Eleven had irrigation complaints, and four discontinued. There were no significant differences by additive. Conclusion SARS-CoV-2+ participants initiating nasal irrigation were over 8 times less likely to be hospitalized than the national rate. Trial Registration [ClinicalTrial.gov][1] Identifier: [NCT04559035][2] Author Approval All authors have filled out ICMJE and approved submission. Conflict of Interest Statement Materials were provided by Neilmed Inc. and Rhinosystems Inc. The study was supported by funding from the Bernard and Anne Gray Donor Advised Fund Community Foundation for Greater Atlanta, Neilmed Inc., and Rhinosystems. No authors have conflict of interest. Question After testing positive for COVID-19, will rapidly initiating nasal irrigation with alkaline or povidone-iodine isotonic solution reduce the risk of morbidity and mortality compared to a national dataset? Findings In this randomized trial of 79 older adults nested in a case:control with the CDC COVID-19 National Dataset, 1.27% of participants initiating nasal irrigation were hospitalized or died, compared to 10.6%, a significant difference. Meaning In older outpatients testing positive for SARS-CoV-2 who initiated nasal irrigation rapidly after diagnosis, risk of hospitalization or death was eight times lower than national rates reported by the CDC. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial NCT04559035 ### Funding Statement Materials were provided by Neilmed Inc. and Rhinosystems Inc. The investigator-initiated study was supported by funding from the Bernard and Anne Gray Donor Advised Fund Community Foundation for Greater Atlanta, Neilmed Inc., and Rhinosystems. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Institutional Review Board Office Augusta University 1120 15th St., CJ-2103 Augusta GA 30912-7621 Email: IRB@augusta.edu Phone: 706-721-3110 http://www.augusta.edu/research/irboffice/ All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes Data is available from the University of Augusta Department of Emergency Medicine Research Office, and online from the CDC COVID-19 Case Surveillance Public Use Data [1]: http://ClinicalTrial.gov [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04559035&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F25%2F2021.08.16.21262044.atom
https://www.medrxiv.org/content/10.1101/2021.08.16.21262044v2

上咽頭を丸洗いできるのは、一般的な喉うがいではなく「鼻うがい」

上咽頭に付着した新型コロナウィルスは3~7日間滞留し体内に取り込まれます。(オミクロン株は発症までの期間が約3日、デルタ株に比べて短いと言われています。)体内に取り込まれてしまう前に「鼻うがい」で副鼻腔と上咽頭に付着しているウィルスを洗い流せば、感染リスクが下がるというわけです。

オミクロン株にこそ上気道を洗える「鼻うがい」

これまでのオリジナル株やデルタ株のウィルス複製は肺で行われるのに対し、オミクロン株は上気道での複製が多いと言われています。上気道とは、鼻から鼻腔、鼻咽腔、咽頭、喉頭のことを指します。この部分を洗浄することで、発症そして重症化と死亡率を下げることができるのです。鼻うがいのメーカーは何社かあるものの、上気道をきちんと洗浄できる製品を選ぶ必要があります。

医師が開発した鼻うがい【サイナスリンス】

ニールメッド株式会社の「サイナスリンス」は医学的根拠のある容量(240ml)、そして特許取得の独自開発ボトルにより、どなたでも簡単に鼻洗浄できます。体液に近い生理食塩水なのでツーンとした刺激がないのも特徴です。また、防腐剤・薬品・香料も不使用なので、どなたでも安心・安全にご使用いただけます。
⿐腔と上咽頭に溜まったウィルス、花粉、細菌などの異物を洗い流すのはもちろんのこと、日々の健康維持としても愛用者が増えている「サイナスリンス」を今こそお試しください。

※本記事は、鼻うがいまたはサイナスリンスが新型コロナウィルス感染症の治療となる、もしくは完治を保証するものではありません。


AIが記事を作成しています